Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 57, Issue 5

Issues

Euthyroid Graves’ disease with spurious hyperthyroidism: a diagnostic challenge

Luca Giovanella
  • Corresponding author
  • Clinic for Nuclear Medicine and Molecular Imaging, Competence Centre for Thyroid Diseases EOC, Bellinzona, Switzerland
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Mauro Imperiali / Dusanka Kasapic
  • Roche Diagnostics International, Medical and Scientific Affairs Department, Rotkreuz, Switzerland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Luca Ceriani
  • Clinic for Nuclear Medicine and Molecular Imaging, Competence Centre for Thyroid Diseases EOC, Bellinzona, Switzerland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Pierpaolo Trimboli
  • Clinic for Nuclear Medicine and Molecular Imaging, Competence Centre for Thyroid Diseases EOC, Bellinzona, Switzerland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2018-09-11 | DOI: https://doi.org/10.1515/cclm-2018-0759

References

  • 1.

    Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 2010;162:1–11.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 2.

    Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829–39.Web of ScienceCrossrefPubMedGoogle Scholar

  • 3.

    Rotondi M, Molteni M, Leporati P, Capelli V, Marino’ M, Chiovato L. Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: an example of selective anti-TSH-receptor immune response. Clin Exp Immunol 2010;162:1–11.Google Scholar

  • 4.

    Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 2014;99:80–9.CrossrefWeb of ScienceGoogle Scholar

  • 5.

    Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler 2016;22:1719–31.Web of ScienceCrossrefPubMedGoogle Scholar

  • 6.

    Grimsey P, Frey N, Bendig G, Zitzler J, Lorenz O, Kasapic D, et al. Population pharmacokinetics of exogenous biotin and the relationship between biotin serum levels and in vitro immunoassay interference. Int J Pharmacokinetcs 2017;2:247–56.CrossrefGoogle Scholar

  • 7.

    Samarasinghe S, Meah F, Singh V, Basit A, Emanuele N, Emanuele MA. Biotin interference with routine clinical immunoassays: understand the causes and mitigate the risks. Endocrine Pract 2017;23:989–98.CrossrefWeb of ScienceGoogle Scholar

  • 8.

    Kummer S, Hermsen D, Distelmaier D. Biotin treatment mimicking Graves’ disease. N Engl J Med 2016;375:704–6.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 9.

    Barbesino G. Misdiagnosis of Graves’ disease with apparent severe hyperthyroidism in a patient taking biotin megadoses. Thyroid 2016;26:860–3.Web of ScienceCrossrefGoogle Scholar

About the article

Corresponding author: Prof. Dr. med. Luca Giovanella, Clinic for Nuclear Medicine and Molecular Imaging, Competence Centre for Thyroid Diseases EOC, Via Ospedale 12, 6500 Bellinzona, Switzerland, Phone: +41-091-8116446, Fax: +41-091-8116444


Received: 2018-07-19

Accepted: 2018-08-16

Published Online: 2018-09-11

Published in Print: 2019-04-24


Author contributions: All the authors have accepted responsibility for the entire content of this submitted

manuscript and approved submission.

Research funding: None declared.

Employment or leadership: DK is a Roche Diagnostics employee.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 57, Issue 5, Pages e94–e96, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2018-0759.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Shonagh Haslam, Jane Oakey, Andrew Brown, Susan Bradshaw, and Martin Myers
Clinical Chemistry and Laboratory Medicine (CCLM), 2019, Volume 57, Number 11, Page e287
[2]
Raffick Bowen, Raul Benavides, Jessica M. Colón-Franco, Brooke M. Katzman, Alagarraju Muthukumar, Hossein Sadrzadeh, Joely Straseski, Ursula Klause, and Nam Tran
Clinical Biochemistry, 2019

Comments (0)

Please log in or register to comment.
Log in